A group of globally acting venture capital and private equity firms with an operating track record of over 30 years manages multiple funds globally. The group’s Life Science Venture arm is looking to provide seed, venture and growth capital to companies in the life science space. The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is a dedicated provider of venture capital to the international pharmaceutical, medical technology and healthcare diagnostics industries, hence looking to invest in companies in sectors of Medical devices, Diagnostic Tools and Platforms, and Specialty Pharmaceuticals that are later stage with strong in human data (Phase IIb and III or on the market) and have very little regulatory risk. The firm’s most recent Life Science Venture Capital Fund is a venture capital fund registered in North America, which focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise. The firm is also less inclined to invest into orphan indications.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture arm of a bank has a €250M evergreen fund, with about half of their investments in the life sciences. The firm invests primarily during series A-B rounds, but will occasionally invest in seed-stage companies as well, and will follow on in subsequent rounds. The firm invests in medical device, diagnostics and digital health companies, and can invest throughout Europe, but focuses mostly in France. The firm will invest anywhere from €1-20M.

The firm invests in medical devices, diagnostics and digital health technologies. Generally, the firm does not invest in therapeutics companies, nor companies in clinical stages. The firm will usually not invest in companies before they have earned their CE mark, and is generally opportunistic to indication.

The firm will only lead or co-lead investments, and always takes a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taipei makes venture stage investments solely in life sciences companies. The firm is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 30% on foreign deals and is currently seeking new opportunities.

The firm is focused on pharmaceuticals, medical devices, diagnostic products, and medical instruments etc. The firm looks for companies with strong intellectual propositions that will develop unmet medical need products. The firm intends to explore joint venture opportunities with foreign companies that can integrate Taiwan’s competitive capabilities in manufacturing, clinical development, and regional sales/distribution.

The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with invested companies closely.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A major reinsurance firm based in Europe makes direct venture stage investments in strategically relevant healthcare startups through a corporate venture capital team, and also invests in life science funds and incubators around the world. The firm invests opportunistically, with a focus on early stage opportunities.

The firm invests strategically in startups that could potentially drive growth in its life and health insurance businesses. In life sciences, the firm is interested in the convergence of life science and insurance tech, and invests in areas such as genomics, digital health, and diagnostics (including diagnostic products focused on consumers as users). The firm is open to investing in any indication area.

The firm’s investments are strategic in nature, and the firm can potentially act as a strategic partner to a portfolio company by supporting product deployment among its network in the health insurance space.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A venture capital firm based in the Netherlands is raising a new fund, with a target of over EUR 100 million. The firm invests all over Europe, and the new fund will have the capacity to invest in the US as well. The firm invests up to EUR 12 million, and may make larger investments from the new fund. The firm generally leads financing rounds.

The firm focuses on therapeutic modalities and platforms, including small molecules, antibodies, cell therapies, and screening platforms including genetic screening. The fund is indication agnostic and typically invests at an early stage.

The firm is a very active investor and typically leads rounds, but can also be a follow-on investor. The firm also sometimes takes part in company generation and new spin-outs from universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A venture capital firm based in Silicon Valley works closely with major incubators globally, through which they are able to identify high-potential, disruptive technologies. The firm is actively investing in early-stage companies and generally participates in Series A to B financing rounds. The initial size of investment depends largely on the company’s stage of development. The firm seeks investments globally.

The firm will consider opportunities in therapeutics, diagnostics, and digital health/healthcare IT. The firm is most interested in data-centric and enterprise technologies. The firm is agnostic to subsector and indication, but the firm will generally avoid medical device companies and early-stage therapeutics companies (i.e. those that take longer than 18 months to commercialize). That said, the firm may consider derisked assets or those that have an accelerated pathway to commercialization. Within healthcare IT technologies, the firm would like to see revenue-generating companies with good consumer traction.

The firm invests in both publicly traded and privately-owned companies. The firm is an active investor and will directly engage in the growth of their portfolio companies through a number of value-ons, including brand building, international expansion, talent recruiting, operation and technical guidance, etc. The firm need not have a fully established management team prior to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A private life science investment firm has a presence in U.K, Canada and multiple locations in U.S. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $0.5 – 3 million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.